CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr. Reddy's Laboratories Ltd. 500124 shares slid 5.01% to 1,224.70 Indian rupees Friday, on what proved to be an all-around ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 ...

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...

Dr. Reddy's Laboratories Ltd.'s profit rose 2% in the third quarter of the current financial year, but missed analysts' ...

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

Prabhudas Lilladher recommended reduce rating on Dr. Reddy's Laboratories with a target price of Rs 1335 in its research ...

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market ...

Dr Reddy’s Laboratories on Thursday said its consolidated net profit increased 2 per cent to Rs 1,413 crore in the third ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched down 0.54% to 1,289.35 Indian rupees Thursday, on what proved to be an all ...